A human monoclonal antibody blocking SARS-CoV-2 infection

Chunyan Wang; Wentao Li; Dubravka Drabek; Nisreen M A Okba; Rien van Haperen; Albert D M E Osterhaus; Frank J M van Kuppeveld; Bart L Haagmans; Frank Grosveld; Berend-Jan Bosch

doi:10.1038/s41467-020-16256-y

A human monoclonal antibody blocking SARS-CoV-2 infection

Chunyan Wang
, Wentao Li
, Dubravka Drabek
, Nisreen M A Okba
, Rien van Haperen
, Albert D M E Osterhaus
, Frank J M van Kuppeveld
, Bart L Haagmans
, Frank Grosveld
, Berend-Jan Bosch

Virology

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.

Original language	English
Article number	2251
Pages (from-to)	1-6
Number of pages	6
Journal	Nature Communications
Volume	11
Issue number	1
DOIs	https://doi.org/10.1038/s41467-020-16256-y
Publication status	Published - 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41467-020-16256-yLicence: CC BY

s41467-020-16256-yFinal published version, 2.77 MBLicence: CC BY

Cite this

@article{2491faf0731849eba9132eb44a0acd6f,

title = "A human monoclonal antibody blocking SARS-CoV-2 infection",

abstract = "The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.",

author = "Chunyan Wang and Wentao Li and Dubravka Drabek and Okba, \{Nisreen M A\} and \{van Haperen\}, Rien and Osterhaus, \{Albert D M E\} and \{van Kuppeveld\}, \{Frank J M\} and Haagmans, \{Bart L\} and Frank Grosveld and Berend-Jan Bosch",

year = "2020",

doi = "10.1038/s41467-020-16256-y",

language = "English",

volume = "11",

pages = "1--6",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - A human monoclonal antibody blocking SARS-CoV-2 infection

AU - Wang, Chunyan

AU - Li, Wentao

AU - Drabek, Dubravka

AU - Okba, Nisreen M A

AU - van Haperen, Rien

AU - Osterhaus, Albert D M E

AU - van Kuppeveld, Frank J M

AU - Haagmans, Bart L

AU - Grosveld, Frank

AU - Bosch, Berend-Jan

PY - 2020

Y1 - 2020

N2 - The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.

AB - The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.

U2 - 10.1038/s41467-020-16256-y

DO - 10.1038/s41467-020-16256-y

M3 - Article

C2 - 32366817

SN - 2041-1723

VL - 11

SP - 1

EP - 6

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 2251

ER -

A human monoclonal antibody blocking SARS-CoV-2 infection

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this